Progress in ALS science and therapeutic development
Latest news
Read our latest announcements on AP-101
June 24, 2026
AL-S Pharma Presents AP-101 Phase 2 Data Supporting Misfolded SOD1 as a Therapeutic Target in ALS at ENCALS 2026
March 19, 2026
Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS
January 07, 2026
AL-S Pharma to present at the upcoming J. P. Morgan 2026 Annual Healthcare Conference on Thursday, January 15
December 05, 2025
AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101 for the Treatment of ALS, Supporting Plans for a Confirmatory Phase 3 Study
September 25, 2025
AL-S Pharma Appoints Internationally Recognized Neurologist and Clinical Trial Expert Prof. Dr. Angela Genge as Chief Medical Officer
September 04, 2025
AL-S Pharma Announces Positive Topline Results From Phase 2 Study of AP-101 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Upcoming events
We regularly participate in scientific conferences, partnering forums, and industry
meetings. Stay up to date on where you can meet us.
November 9-11, 2026
BIO-Europe
Where the global community of biopharma C‑suite, investors and partners meet to navigate complexity, forge the connections that matter, and accelerate the path from innovation to impact.
December 9-11, 2026
37th International Symposium on ALS/MND
The biggest annual conference dedicated to ALS and MND research.
July 5-9, 2027
Pan-Asian Consortium for Treatment and Research in ALS (PACTALS)
Where the global community of biopharma C‑suite, investors and partners meet to navigate complexity, forge the connections that matter, and accelerate the path from innovation to impact.
July 5-9, 2027
20th International Congress on Neuromuscular Diseases (ICNMD)
Updated view on neuromuscular disorders and networking opportunities to increase international experience and collaborations.